Portopulmonary Hypertension
Clinics in Liver Disease · 2023-02 · 27 (1) · 71-84
DOI: 10.1016/j.cld.2022.08.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2023-02. Verfasst von Yu Kuang Lai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary, Allergy and Critical Care, Department of Medicine, Stanford University, 300 Pasteur Drive, Room H3143, Palo Alto, CA 94304, USA. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Hypertension, Portal, Liver Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
PoPH is a well-recognized complication of portal hypertension with or without cirrhosis and is classified as a subset of PAH. Identification of PoPH is crucial as it has a major impact on prognosis and liver transplant candidacy. Echocardiogram is the initial screening tool of choice and the patient should proceed to RHC for confirmation. PAH-directed therapy is the treatment of choice, allowing the patient to achieve a hemodynamic threshold to undergo a liver transplant safely.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonary, Allergy and Critical Care, Department of Medicine, Stanford University, 300 Pasteur Drive, Room H3143, Palo Alto, CA 94304, USA.
- Stanford University School of Medicine, 430 Broadway, Pavilion C, 3rd Floor, Redwood City, CA 94063, USA. Electronic address: pkwo@stanford.edu.
Zitieren
APA
Lai, Y. K., & Kwo, P. Y. (2023). Portopulmonary Hypertension. Clinics in Liver Disease, 27(1), 71-84. https://doi.org/10.1016/j.cld.2022.08.002
Vancouver
Lai YK, Kwo PY. Portopulmonary Hypertension. Clinics in Liver Disease. 2023;27(1):71-84. doi:10.1016/j.cld.2022.08.002
BibTeX
@article{Lai2023,
author = {Lai, Yu Kuang and Kwo, Paul Y},
title = {Portopulmonary Hypertension},
journal = {Clinics in Liver Disease},
year = {2023},
volume = {27},
number = {1},
pages = {71--84},
doi = {10.1016/j.cld.2022.08.002}
}
EUVIMED